



Blake, Cassels & Graydon LLP  
Barristers & Solicitors  
Patent & Trademark Agents  
199 Bay Street  
Suite 4000, Commerce Court West  
Toronto ON M5L 1A9 Canada  
Tel: 416-863-2400 Fax: 416-863-2653

October 2, 2023

Reference: 18100/25

**VIA SEDAR+**

Ontario Securities Commission, as principal regulator  
Alberta Securities Commission  
British Columbia Securities Commission  
Financial and Consumer Affairs Authority of Saskatchewan  
The Manitoba Securities Commission  
Financial and Consumer Services Commission (New Brunswick)  
Nova Scotia Securities Commission  
Superintendent of Securities, Prince Edward Island  
Superintendent of Securities, Newfoundland and Labrador

**RE: Medexus Pharmaceuticals Inc. (the “Corporation”) – Final Short Form Prospectus**

Dear Sirs/Mesdames:

We refer to the final short form prospectus (the “**Prospectus**”) of the Corporation dated October 2, 2023 relating to an offering of units, each comprised of one common share in the capital of the Corporation and one-half of one common share purchase warrant.

We hereby consent to the references to our firm name on the cover page of the Prospectus, and under the headings “Plan of Distribution”, “Legal Matters” and “Interests of Experts” in the Prospectus and to the reference to our firm name and to the use of our opinion under the heading “Eligibility for Investment” in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations (as defined in the *Securities Act* (Ontario)) in the information contained therein that is derived from our opinion referred to above or that is within our knowledge as a result of the services we have performed in connection with such opinion.

Yours very truly,

*“Blake, Cassels & Graydon LLP”*